Interleukin 2 (IL-2). a T-cell-derived lymphokine, activates non-specific cytotoxic lymphocytes, which are capable of lysing tumour cells without exerting lytic activity against normal cells (Grimm et al.. 1982) . On the basis of this anti-tumour effect, IL-2 alone or in combination with other cytokines or chemotherapeutic agents is used as a treatment in advanced cancer or as an adjuvant immunotherapy (Rosenberg et al., 1987; Paciucci, 1992; Vlasveld et al., 1992) . The anti-tumour activities of IL-2 are dose and schedule related, as shown in various clinical studies (Rosenberg et al., 1989) and in experimental animals (Rosenberg et al., 1985) . However, high-dose IL-2 regimens are limited by substantial toxicity, in particular pulmonary and systemic oedema, decreased systemic resistance, increased cardiac output, hypotension and oliguria mimicking a septic shock-like condition (Lotze et al., 1986; Parkinson, 1988) .
Intravenous injection of IL-2 induces extravasation of labelled albumin in experimental animals (Rosenstein et al., 1986; Harms et al., 1989) . However, the exact mechanisms by which IL-2 mediates the increase in vascular permeability are largely unknown. Some authors have demonstrated a direct effect of IL-2 in vitro on vascular permeability (Fairman et al., 1987; Downie et al., 1992) , whereas others have suggested that IL-2 exerts this effect by induction of various cytokines (Mier et al.. 1988; Fraker et al., 1989; Edwards et al., 1992) such as tumour necrosis factor alpha (TNF-m) ['5I ]uptake by the thyroid gland. The TER of ['5Ialbumin was measured as described previously (Ballmer et al., 1992 (Ballmer et al., , 1994 Plasmna protein concentrations 'Negative' (i.e. normally decreasing in the acute-phase reaction) acute phase proteins, i.e. albumin, prealbumin and transferrin, and 'positive' (i.e. normally increasing in the acute-phase reaction) acute-phase proteins, i.e. C-reactive protein (CRP) and fibrinogen, were also measured before the first and 6 h after the second IL-2 administration. CRP was determined by turbidimetry (Boehringer, Mannheim, Germany) on a Hitachi autoanalyser (BM 717), transferrin by spectrophotometry (Uni-Kit, Roche, Switzerland), prealbumin by nephelometry (Behring, Marburg, Germany) and albumin with bromcresol green (Doumas et al., 1971 Table I the characteristics of the patients are summarised. Eight patients suffered from superficial spreading melanoma (Clark level HII-IV, Breslow level 0.9-3.3 mm), one from nodular melanoma (Clark IV, Breslow 1.95 mm) and one from conjunctival melanoma. Four patients had locoregional lymph node metastases and one had satellite metastases. All patients were surgically treated in a curative way and were regarded as tumour free when they entered the study protocol. Table II summarises the values of plasma albumin concentrations, IAM, TER and J4b. Plasma albumin concentration decreased from 46 ± 1 g 1' before to 43±3gl-1 after IL-2 treatment (P=0.01), whereas IAM, the intravascular albumin mass, remained stable (136 ± 18 g before vs 136 ± 18 g after IL-2 administration) as a result of a slight increase in plasma volume (2987 ± 452 ml and 3163 ± 477 ml respectively, P<0.05). TER and the absolute albumin outflux (J4b) showed a marked elevation from 9.4 ± 2.7% h-' to 14.9 ± 3.3% h-' (P<0.001) and from 159±28mgh-'kg-' to 261±44mgkg-'lh-r vely ( Figure 1 ). significantly from 2.0 ± 2.4 mg I`to 13.8 ±11.8 mg I( P<0.01), whereas fibrinogen moderately increased (2.8 ± 0.5 g I`before vs 3.2 ± 0.5 g 1`after IL-2 administration, P = 0.09) and blood sedimentation rate (BSR) ained unchanged (see Table Ill ). Cytokine plasma concentrations are summarised in Table  IV. IL-2 plasma concentrations were not detectable before treatment and inreased to 549 ± 315 U mlP' (P<0.001) 6 h after the second IL-2 adminisation. The IL-2-inducible cytokines IFN-y and TNF-a did not show a consistent response to IL-2 injections. IFN-y was not measurable in six patients before and after treatment In two patients it increased from 0 to 9 U ml-I and from 0 to 13 U mlr-, and in another patient it dropped from 32 U ml1-to 0. TNF-a was not detectable before IL-2 adminitation in seven patients. After treatment it showed slightly elevated concentrations in five patients and ained nged in two patients. In three patients TNF-a was initially elevated and decreased under theapy.
IL-6, however, was not detectable in all ten patients before treatment, but increased in seven patients to 7±6 pg ml1 (P<0.01, range 5.3-16.5pgmml-) after 1L-2 adminisation. After discontinuing IFN-a therapy I day before admission, baseli values were initially elevated (22 + 18 IU ml-') and fell 24h later to 14±27IUml-' (P=0.26). (Fleck et al., 1985; Ballmer et al., 1992 Ballmer et al., , 1994 . TER is an estimate of the albumi losses across the vascular endothelium, and can reliably be measured by intravenous injection of labelled albumin (Parving, 1973; Rossing et al., 1976; Fleck et al., 1985; Ballmer et al., 1992 Ballmer et al., , 1994 . In healthy human subjects TER is approximately 4-7% per hour, i.e.
120% of the intravascular albumin pool escapes per day with subsequent redistribution.
In many pathological conditions, in paricular in most inflammatory , TER can markedly increase. Thus, we reported a substantial increase in TER in patients suffering from acute infectious disease (Balmer et al., 1994) . Fleck et al. (1985) showed a 2-fold elevation of TER within a few hours after a surgical trauma. The exact mechanism, however, regulating the vascular permeability is largely unknown.
In the present study, TER and Jwb (the absolute outflux of labeled albumin) increased by roughly 60% after IL-2 injections, and, simultaneously, plasma albumin concentration slightly decreased, whereas plasma volume correspondingly increased. Thus, the intravascular albumin mass, i.e. the product of plasma albumin concentration and plasma volume, was unaffected by the increase in TER/Jwb. This was not entirely unexpected, since in an earlier study on the impact of acute inflammatory diseases on TER (Ballmer et al., 1994) we had already observed a slightly positive (instead of the expected negative) correlation between TER and plasma albumin concentrations. Apparently, the massive increase in TER/Jab produced by IL-2 injections can be compensated for. We hypothesise that (a) direct redistribution of albumin back to the intravascular space occurred and (b) the lymphatic system retured a substantial amount of the accessory albumin/fluid that had escaped as a result of the increase in vascular permeability. Physiologically, the lymphatic system returns the entire plasma protein pool per day to the intravascular space (Granger, 1970) . Under inflammatory conditions, the lymphatic system can increase its transport capacity several times (Granger, 1970; Balhmer et al., 1994 ). An overload of this transport capacity leads to clinically manifest oedema formation. In our patients, however, no signs of fluid retention, i.e. oedema or gain in body weight, occurred, thus supporting the hypothesis that direct redistribution and/or lymphatic return was potent enough to compensate for the increase in TER and Ja. The fact, that the lymphatic return might be an important mechanism to compensate for the increase in TER is supported by a recent study, in which an IL-2-induced increase in lymphatic flow and in tansvascular fluid and protein filtration was shown in experimental animals (Harms et al., 1989 ).
The present study was also an attempt to identify whether IL-2 administration has any direct effects on vascular permeability in humans. In various in vivo and animal studies IL-2 was shown to be an important pathogenetic factor affecting vascular permeability. Thus, Harms et al. (1989) demonstrated an IL-2-induced increase in pulmonary fluid and protein permeabiity in sheep, and Downie et al. (1992) found a direct in vitro stimulatory effect of IL-2 on albumin permeability in human and bovine endothelium. In contrast, Edwards et al. (1992) suggested that IL-2 is not a direct stimulatory factor for vascular permeability: when IL-2 was given together with anti-TNF-a antibody, the albumin extra- The patients in the present study were already receiving treatment with IFN-a when they were admitted to hospital for IL-2 injections. When compared with our own results in healthy volunteers (Ballmer et al., 1992 (Ballmer et al., , 1993 (Ballmer et al., , 1994 and those in the literature (Fleck et al., 1985) , the TER was slightly higher before IL-2 injections than normal. Although we cannot rule out a certain stimulatory effect of IFN-a, this is not very likely, since IFN-a administration was discontinued before IL-2 injections. Furthermore, we cannot exclude the possibility that IFN-a primed the patients' susceptibility towards the IL-2-induced increase in the vascular permeability. In line with this, IFN-a given with IL-2 had a synergistic effect on the vascular leak in the lungs of experimental animals (Siegel et al., 1991) .
In conclusion, subcutaneous IL-2 injection induced a marked elevation in TER/J,% in melanoma patients, but this had no effect on the intravascular albumin mass, suggesting that compensatory mechanisms, such as the lymphatic return, are powerful enough to equilibrate for fluid/protein extravasation. Although IL-2 might have some direct stimulatory effects on vascular permeability in humans, a direct effect of IL-2 could only be verified by simultaneous administration of antibodies against the IL-2-inducible cytokines. The administration of such antibodies in patients with malignant melanoma, however, might abrogate anti-tumoral effects of IL-2.
